Immunotherapeutic agents are increasingly becoming incorporated into clinical practice; however, there is still much to learn, including their optimal combinations, sequencing and usage. In this interview, Martin Reck, MD, PhD, of the Lung Clinic Grosshansdorf, Grosshansdorf, Germany, discusses whether we can improve the efficacy of immunotherapy in lung cancer patients who have not been selected for their high PD-L1 expression. This video was recorded at the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland.
Transforming outcomes in advanced lung cancer: immunotherapy in unselected patients
